In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell’s own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from […]
Metabolic syndrome refers to a class of complex metabolic disorders, including adipose tissue accumulation, insulin resistance, diabetes, hyperinsulinemia, hypertension, and dyslipidemia, characterized by high levels of triglycerides (TG) and high-density […]
In late 2014, the PARP inhibitor Olaparib was approved to treat ovarian cancer with BRCA mutations. Since then, research in the field of PARP has received extensive attention, especially in […]
BOC Sciences has directed sincere efforts toward the R&D of small-molecule inhibitors (inhibitors, agonists, and modulators), which greatly free researchers from material outsourcing and selection workload.
Compared with biological drugs, small molecule drugs have greater advantages in R&D cost and process maturity, and they are still the main battlefield for drug research and development. According to […]
Protein degradation targeted chimera (PROTAC) PROTAC technology began in 2001 that uses the ubiquitin-proteasome system (UPS), the intracellular “cleaner” for cleaning up denatured, mutated, or harmful proteins in cells. PROTAC, which uses […]
Preface Judging from the global drug sales trend in recent years, biological drugs have begun to become popular, while sales of small molecular drugs are declining. Innovations in research and […]